Abstract
To explore the SARS-CoV-2 early pandemic in Algeria, a dataset comprising forty-three genomes originating from SARS-CoV-2 sampled from Algeria and other countries worldwide, from 24 December 2019 through 8 March 2020, of which, were thoroughly examined. While performing a multi-component analysis regarding the Algerian outbreak, the toolkit of phylogenetic, phylodynamic, haplotype analyses and genomic analysis were effectively implemented. We estimated the TMRCA in reference to the Algerian pandemic and highlighted both the introduction of the disease originating in France and the missing data depicted in the transmission loop. Most importantly, we unveiled mutational patterns, recombination events and the relatedness regarding the Algerian sequences to the dataset. Our results revealed the unique amino-acid replacement L129F in the orf3a gene in Algeria_EPI_ISL_418241. Additionally, a connection between Algeria_EPI_ISL_420037 and sequences originating from the USA was observed through a USA characteristic amino-acid replacement T1004I in the nsp3 gene, found in the aforementioned Algerian sequence. Lastly, we assessed the Algerian mitigation measures regarding disease containment using statistical analyses.
Author summary A novel human coronavirus, specifically SARS-CoV-2, emerged in China in late 2019. In Algeria, the contact tracing revealed the introduction of the disease originated in France, however, the intricate dynamics regarding the disease remain unexplored. In this study, we attempt to portray our perspective regarding the evolutionary, genetic and epidemiological aspects of the early pandemic in Algeria during the spring of 2020, through the use of time scaled phylogeny, phylodynamic and mutational pattern characterization and exploration. Additionally, we assessed the efficiency of the implemented mitigation measures using statistical analysis. The results supported the virus introduction from France and highlighted an Algerian characteristic amino-acid replacement in addition to a relatedness to the USA sequences. Moreover, we revealed an indirect contamination among the three sampled patients. Therefore, our analysis is a starting point for further investigations and emphasize the importance regarding intensive sequencing and genome exploration for mitigation measures implementation, and both drug and vaccine development.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding was recieved for the current work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Exemption
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data are available within the manuscript and the supplimentary material file.
